在肺状细胞癌中准mTORC2通过PSGL-1-VISTA轴提高了通过PSGL-1-VISTA轴的抗瘤免疫力

Verra M Ngwa1, Yoonha Hwang1, Wenqiang Song1,2

  • 1Department of Medicine, Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN, USA.

Cancer gene therapy
|July 10, 2025
PubMed
概括

准mTORC2通路可以改善肺状癌 (LUSC) 的免疫反应. 这项研究揭示了mTORC2抑制减少瘤生长和增强T细胞活性,为LUSC患者提供新的治疗策略.

相关概念视频

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K